FDA advisors said the benefits seem to outweigh any possible risks, and the agency will decide whether to approve it by December 8
Gene-Editing Treatment for Sickle Cell Disease Moves Closer to Approval
FDA advisors said the benefits seem to outweigh any possible risks, and the agency will decide whether to approve it by December 8
